Contact us










SeqOne S.A.S

Address
SeqOne S.A.S.
C/IRMB - Hopital St Eloi
80 Avenue Augustin Fliche
34090 Montpellier France
Contact
Jean-Marc Holder
+33 6 03 24 57 56
jm.holder@seqone.fr

SeqOne, lauréate du concours i-Lab 2017 pour un projet visant à démocratiser l’analyse ADN au service de notre santé

Des avancées scientifiques récentes font de la médecine génomique un réel avantage dans le traitement de nombreuses maladies. Cependant le coût d’interprétation des données est aujourd’hui plus élevé que le séquençage en lui-même freinant la démocratisation de cette approche innovante.  “SeqOne vise à réduire ce coût mettant ainsi à portée de tous des tests génétiques […]

> Read the full article here

SeqOne wins prestigious iLab grant to improve genomics analysis software in healthcare

Montpellier 12th of July, 2017:  SeqOne a French start-up in the genomic medicine market is proud to announce that it has been awarded an i-Lab grant by the Ministry of Education and Technology.  i-Lab is a national competition open to all French start-ups designed to identify the most promising technical innovations by France’s most forward-thinking […]

> Read the full article here

FDA approves gene-altering leukemia therapy in US

The New York times today reported that the FDA had approved the first therapy that involves human genetic modification.   The procedure developed by Novartis to combat leukemia will be the first gene therapy ever to reach the market in the US.  Read the full article here.

> Read the full article here

CRISPR gene editing technology implications

The following video was featured in an article in Futurism.com that talks about the first efforts to genetically engineer humans.  You can read the article here.

> Read the full article here

CRISPR gene editing technology tested on a human

The following video was featured in an article in Futurism.com that talks about the first efforts to genetically engineer humans.  You can read the article here.

> Read the full article here

SeqOne, lauréate du concours i-Lab 2017 pour un projet visant à démocratiser l’analyse ADN au service de notre santé

Des avancées scientifiques récentes font de la médecine génomique un réel avantage dans le traitement de nombreuses maladies. Cependant le coût d’interprétation des données est aujourd’hui plus élevé que le séquençage en lui-même freinant la démocratisation de cette approche innovante.  “SeqOne vise à réduire ce coût mettant ainsi à portée de tous des tests génétiques […]

> Read the full article here

Myriad Genetics embroiled in breast-cancer data fight — again

Genetic-testing firm Myriad Genetics is facing a legal challenge from people who say the company refused to give them access to their own genomic data, in violation of a US government rule on medical records. Although Myriad has now agreed to release the data to those individuals, the patients are pressing ahead with their complaint […]

> Read the full article here

After a prominent gene-testing firm declined to give patients their complete data, ACLU filed a legal complaint

Four people with a family history of cancer, or who have cancer themselves, lodged a complaint this afternoon with the U.S. Department of Health and Human Services (HHS). It alleges that Myriad Genetics, a prominent genetic testing company, broke a federal rule by withholding genomic data that are rightfully theirs. At least one plaintiff wants to share her […]

> Read the full article here

Myriad Genetics embroiled in breast-cancer data fight — again

Genetic-testing firm Myriad Genetics is facing a legal challenge from people who say the company refused to give them access to their own genomic data, in violation of a US government rule on medical records. Although Myriad has now agreed to release the data to those individuals, the patients are pressing ahead with their complaint […]

> Read the full article here

After a prominent gene-testing firm declined to give patients their complete data, ACLU filed a legal complaint

Four people with a family history of cancer, or who have cancer themselves, lodged a complaint this afternoon with the U.S. Department of Health and Human Services (HHS). It alleges that Myriad Genetics, a prominent genetic testing company, broke a federal rule by withholding genomic data that are rightfully theirs. At least one plaintiff wants to share her […]

> Read the full article here

Next generation genomic analysis for next generation healthcare